From GlobeNewswire: 2025-05-28 17:54:00

Fate Therapeutics, Inc. will present clinical and preclinical data on their off-the-shelf cell therapy product platform at EULAR 2025 in Barcelona. The data will include information on FT819, an off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate for systemic lupus erythematosus. The company’s iPSC product platform uses Sword and Shield technology for multi-antigen targeting, eliminating the need for conditioning chemotherapy. Presentation details are available on the EULAR 2025 website. Fate Therapeutics’ unique platform combines human iPSCs with single-cell selection to create clonal master iPSC lines, enabling off-the-shelf cellular immunotherapies.

For more information, visit www.fatetherapeutics.com. This release contains forward-looking statements and highlights the risks and uncertainties associated with the Company’s research and development programs and product candidates. Fate Therapeutics is providing this information as of the release date and is not obligated to update any forward-looking statements. Contact Precision AQ for more information.



Read more at GlobeNewswire: Fate Therapeutics Announces Phase 1 Data Presentation of